Literature DB >> 10819911

Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635.

E Hirani1, J Opacka-Juffry, R Gunn, I Khan, T Sharp, S Hume.   

Abstract

Positron emission tomography (PET), following an intravenous injection of [carbonyl-(11)C]WAY 100635, was used to image central 5-HT(1A) receptors in rat following pretreatment with graded doses of (-)-pindolol (0.001-3 mg/kg, i.v.). The use of PET had advantages over ex vivo radioligand binding methods in that it produced parametric image volumes and reduced errors due to inter-rat variability. Time-radioactivity curves from regions of interest (ROI) acquired from individual rats enabled the estimation of specific binding of the radioligand using a compartmental model with reference tissue input. Binding potential (BP) of [(11)C]WAY 100635 was estimated for frontal cortex and hippocampus (postsynaptic), and midbrain raphe nuclei (presynaptic). In the latter ROI, pindolol dose-dependently decreased BP. The saturation curve could be fitted to a single-site model up to the lowest dose of pindolol used, giving an ED(50) (dose to cause 50% occupancy) value of 0.26 +/- 0. 05 mg/kg, and inclusion of control (nonpindolol-treated) rats did not affect the fit. In contrast, in cortex and hippocampus ROI, low doses of pindolol caused an increase in BP compared with controls. Pindolol doses greater than approximately 0.1 mg/kg, resulted in a dose-dependent decrease in BP, and ED(50) values in cortex and hippocampus were estimated as 0.44 +/- 0.13 and 0.48 +/- 0.12 mg/kg, respectively. The increase in [(11)C]WAY 100635 binding at low pindolol doses is feasibly related to a decrease in basal receptor occupancy following reduced release of endogenous 5-HT. Considering the apparently greater potency of pindolol at the midbrain raphe ROI, this effect could be mediated via agonist activity at the autoreceptor. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819911     DOI: 10.1002/(SICI)1098-2396(20000615)36:4<330::AID-SYN10>3.0.CO;2-H

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Authors:  Benjamin Vidal; Sylvain Fieux; Jérôme Redouté; Marjorie Villien; Frédéric Bonnefoi; Didier Le Bars; Adrian Newman-Tancredi; Nicolas Costes; Luc Zimmer
Journal:  Neuropsychopharmacology       Date:  2018-07-06       Impact factor: 7.853

2.  Initial in vivo PET imaging of 5-HT1A receptors with 3-[(18)F]mefway.

Authors:  Dustin W Wooten; Ansel T Hillmer; Dhanabalan Murali; Todd E Barnhart; Joanne P Thio; Alisha K Bajwa; Ali A Bonab; Marc D Normandin; Mary L Schneider; Jogeshwar Mukherjee; Bradley T Christian
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

Review 3.  Transcriptional regulation of the 5-HT1A receptor: implications for mental illness.

Authors:  Paul R Albert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

Review 4.  A review of the literature on neuroimaging of serotoninergic function in Alzheimer's disease and related disorders.

Authors:  E Salmon
Journal:  J Neural Transm (Vienna)       Date:  2007-02-19       Impact factor: 3.575

Review 5.  Measuring endogenous 5-HT release by emission tomography: promises and pitfalls.

Authors:  Louise M Paterson; Robin J Tyacke; David J Nutt; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-28       Impact factor: 6.200

6.  Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain.

Authors:  Takeaki Saijo; Jun Maeda; Takashi Okauchi; Jun-ichi Maeda; Yasunori Morio; Yasuhiro Kuwahara; Masayuki Suzuki; Nobuharu Goto; Toshimitsu Fukumura; Tetsuya Suhara; Makoto Higuchi
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.